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Confronting the Opioid Crisis: Practical Pain
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Abstract: The United States is in the midst of an opioid crisis. Clinicians have been part of the problem because of
overprescribing of narcotics for perioperative pain management. Clinicians need to understand the pathophysiology and
science of addiction to improve perioperative management of pain for their patients. Multiple modalities for pain management
exist that decrease the use of narcotics. Physical strategies, cognitive strategies, and multimodal medication can all provide
improved pain relief and decrease the use of narcotics. National medical societies are developing clinical practice guidelines
for pain management that incorporate multimodal strategies and multimodal medication. Changes to policy that improve
provider education, access to naloxone, and treatment for addiction can decrease narcotic misuse and the risk of addiction.

RQ 

Epidemiology
The United States ﬁnds itself in the midst of the current opioid
crisis because of the alarming rise in the number of prescriptions for opioids and the number of pills that have been diverted for nonmedical use over the past few decades1-3. The
number of opioid-related deaths has more than quadrupled
since 1999, and is now higher than deaths from illicit drugs
such as heroin and cocaine combined, and even higher than
deaths from motor-vehicle collisions4. The Surgeon General
highlighted this crisis in 2016 in the report “Facing Addiction
in America.”5 In addition to the rising death toll, opioids have
had a major impact on public health because of related issues.
For every 1 prescription opioid death, there are 20 specialty
substance-abuse treatment admissions, 45 emergency department visits for nonmedical use and adverse events, 156 people

with substance use disorder and dependence, and 533 people
using the drugs nonmedically overall5,6.
The opioid crisis has been largely fueled by the oversupply of prescription opioids in circulation, which leads to diversion from friends and families to illicit use4. The Surgeon
General’s report also conﬁrmed that there has been a concomitant resurgence in the number of deaths related to heroin, and
an even greater rise in the number of deaths related to illicit
fentanyl2. Therefore, the opioid crisis in the U.S. may be even
worse than reported when considering the additional effects
from related illicit drugs on death rates and the aforementioned
other health and societal issues.
The opioid crisis in the U.S. has been referred to as an
epidemic, a term that is typically reserved for widespread phenomena. When looking at international data, there has been a
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global increase in the amount of opioids utilized in terms of
morphine milligram equivalents per capita over the past few
decades that mimics the data seen in the U.S.; therefore, the
opioid crisis could be considered an international epidemic or
even a pandemic1. However, when one looks more closely at the
data, it can be argued that there are actually 2 facets to the global
opioid situation. In much of the developed world (U.S., Canada,
Europe, and Australia), the rates of opioid use per capita are
extremely high, while in much of the developing world (Central
Asia, Central and South America, and Africa) the rates of opioid
use per capita are extremely low; in many of these developing
nations, there are not enough medications to manage acute severe
pain or more chronic cancer-related pain1.
There are approximately 1 million physicians in the U.S.,
and nearly 2% (;20,000) are practicing orthopaedic surgeons7.
Although small in number, orthopaedic surgeons (7.7%) are
the fourth highest prescribers of opioids, behind primary care
physicians (28.8%), internists (14.6%), and dentists (8.0%), for
the percentage of prescriptions dispensed by U.S. retail pharmacies8. There are substantially more members of each of those
specialties, with approximately 109,000 primary care physicians, 111,000 internists, and 195,000 dentists8,9. Orthopaedic
surgeons prescribe more narcotic medication per clinician
when compared with any other specialty8,9. Musculoskeletal
conditions (surgical and nonsurgical) can be associated with
substantial acute and chronic pain. Many patients who are
treated by primary care physicians, internists, and emergency
room physicians have musculoskeletal pain. Over the past few
decades, the use of opioids for musculoskeletal pain diagnoses
in ambulatory settings, including primary care clinics and
emergency departments, has doubled10,11. Therefore, the impact
of orthopaedic surgeons on the management of musculoskeletal pain can have an effect within the specialty and an even
greater potential impact outside of the specialty by decreasing
the utilization of opioids as ﬁrst-line treatment and monotherapy for acute and chronic musculoskeletal conditions.
Science of Addiction
Opioid analgesics are a class of medication that works on mu
receptors in the brain and the spinal cord. Speciﬁcally, these mu
receptors (also known as opioid receptors) inhibit gammaaminobutyric acid (GABA), which is the chief inhibitory neurotransmitter in mammals. As the opioids activate these mu
receptors and inhibit GABA, dopamine is released (since GABA
normally inhibits dopamine). Increased dopamine, speciﬁcally
in the nucleus accumbens, increases feelings of pleasure, leading to the positive associations that patients have with opioid
ingestion that are speciﬁcally related to addiction.
Increasing opioid strength also can be related to addiction and death12. Speciﬁcally, commonly used medications
such as fentanyl and hydromorphone are substantially stronger than morphine. In addition, medications that are thousands of times stronger are now starting to be disseminated on
the black market13.
Addiction is deﬁned as a “chronic, relapsing brain disease that is characterized by compulsive drug seeking and use,
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despite harmful consequences.”14 Addiction is now considered
a disease of the brain due to actual changes seen in the brain
that may or may not be permanent15. In contrast, physical
dependence is related to regular use of a substance; speciﬁcally, when the patient adapts to that regular use, he or she
may have physical symptoms when the substance is stopped14.
Substance use disorder is deﬁned as a “problematic pattern of use of an intoxicating substance, leading to clinically
signiﬁcant impairment or distress,”16 as manifested by at least 2
of the characteristics that are listed in Table I occurring within a
12-month period16.
Addiction in the brain acts in a cycle, starting with binging or becoming intoxicated (stage 1), followed by withdrawal
or feeling negative (stage 2), and then ﬁnally moving to “preoccupation/anticipation” (stage 3), which leads back to stage 117. It is
important to note that addiction is separate from, but may be
related to, drug abuse. Abuse is the use of illegal drugs or the
misuse of prescription or over-the-counter medications, which
can lead to negative consequences in personal relationships, legal
encounters, and physical risks14. The abuse of prescription opioids
has increased substantially in recent years; overdose deaths alone
increased ﬁvefold from 1999 to 201618.
Certain factors are strongly associated with the risk of
opioid overdose or addiction, and clinicians should take care to
evaluate their patients for these risks: age >65 years or

TABLE I Characteristics of Substance Use Disorder
The substance is often taken in larger amounts or over a longer
period than it was intended
There is a persistent desire or unsuccessful effort to cut down or
control use of the substance
A great deal of time is spent in activities necessary to obtain the
substance, use the substance, or recover from its effects
Craving or a strong desire or urge to use the substance
Recurrent use of the substance, resulting in a failure to fulﬁll major
role obligations at work, school, or home
Continued use of the substance despite having persistent or
recurrent social or interpersonal problems caused or exacerbated
by the effects of its use
Important social, occupational, or recreational activities are given
up or reduced because of use of the substance
Recurrent use of the substance in situations in which it is physically
hazardous
Use of the substance is continued despite having knowledge
of having a persistent or recurrent physical or psychological
problem that is likely to have been caused or exacerbated by
the substance
Tolerance: a need for markedly increased amounts of the
substance to achieve intoxication or desired effect OR a markedly
diminished effect with continued use of the same amount of the
substance
Withdrawal: characteristic withdrawal syndrome for that substance
OR the substance (or a closely related substance) is taken to
relieve or avoid withdrawal symptoms
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adolescents, sleep apnea and breathing disorders, kidney or
liver disease, depression, other substance use disorders, and a
history of overdose19. In addition, we as clinicians can exacerbate risk factors via the medication itself, including use of
morphine milliequivalent doses of >100 daily, long-acting or
extended-release medications, and combining benzodiazepines
with opioids19. Clinicians should particularly be on high alert
for patients in the ﬁrst couple of weeks after medication initiation and for those patients who are using opioids for >3
months since these patients are at particularly high risk of
overdose and addiction, respectively19. Patients taking narcotics
for an extended period of time may be considered for referral to
a mental health provider or addiction treatment.
Prescribing Practices and Recommendations
Because of the frequency of opioid use in routine orthopaedic
procedures and the high risk of abuse and addiction associated
with opioids, the Orthopaedic Trauma Association (OTA)
developed evidence-based guidelines for pain management20.
Hsu et al. reviewed these guidelines since the vast majority of
orthopaedic injuries are cared for in community hospitals by
orthopaedic surgeons who are not afﬁliated with the OTA. We
hope that wider dissemination of this information improves
patient care, decreases diversion of narcotics, and decreases
abuse and addiction.
Clinical Management
With our patients, balancing comfort and safety with pain
alleviation means evolving beyond the opioid monotherapy
strategies that have dominated the past 3 decades21. While
opioids have some beneﬁt in the acute setting, multimodal
pain alleviation involves pharmaceutical, physical, and cognitive strategies. The recently published Clinical Practice Guidelines (CPGs) from the OTA detail the evidence behind
practical solutions for a multimodal approach to acute injury
or surgery20.
One barrier to this balanced approach has been orthopaedic surgeons’ fear of utilizing nonsteroidal anti-inﬂammatory
drugs (NSAIDs) in the setting of bone healing21. More recent
evidence-based reviews suggest that this fear was not well
founded scientiﬁcally20,22. NSAIDs have not been indicated in
increasing the risk of nonunion or other complications, especially with perioperative use. Including other medications such
as gabapentin23 and acetaminophen can help to decrease the
dose and duration of opioid use while providing appropriate
pain relief. Adequate and precise opioid prescription allows the
concomitant use of additional acetaminophen, as detailed in
the medication taper method in the OTA CPGs20. Adequate
prescribing practices can be based on using medications that
the patient has recently required postoperatively or historical
use with similar injuries to guide the prescription of medication at hospital discharge24.
Physical strategies alter pain receptors by blocking ﬁbers
or providing superﬁcial alternative stimulation to blunt deep
pain. Physical strategies for pain alleviation include nerve
blocks25 and ﬁeld blocks26,27. Cryotherapy, or ice therapy, has
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demonstrated reasonable clinical beneﬁts with pain relief28-30
that is consistent with basic science mechanisms31-33. Cryotherapy can even be effective under splints or casts34-37. Transcutaneous electrical nerve stimulation (TENS) has been shown to
improve pain relief while decreasing opioid consumption in a
variety of settings38-40.
Cognitive strategies for pain alleviation target the wellestablished relationship between anxiety and pain41-44. While
cognitive strategies can be resource intensive, some, including
music therapy and aromatherapy, are very scalable. Both music
therapy and aromatherapy have been shown to decrease anxiety and pain in evidence-based reviews45. Cognitive behavioral
therapy can be effective46, but it is difﬁcult to scale unless webbased strategies are employed47,48.
Perioperative analgesia in patients with chronic opioid
use should be managed with a multimodal analgesia regimen.
An acute pain service (APS) can assist with coordinating
inpatient and outpatient medication. Having only 1 prescriber is optimal for patients who have been using illicit
opioids or for patients who have been misusing prescription
opioids.
Patients who have been consuming routine and scheduled oral opioids prior to surgery should continue baseline
medication on the morning of surgery and throughout the
postoperative period. Transdermal fentanyl patches should be
converted to an intravenous morphine equivalent dose because
of alterations in fentanyl release that are secondary to perioperative ﬂuid shifts and body temperature changes. When oral
medications cannot be consumed because of NPO (nothing by
mouth) status or when patients are unable to receive medications by mouth, a 24-hour morphine equivalent dose should be
calculated to provide the equivalent in intravenous medication
or transdermal buprenorphine until oral medications can be
resumed.
Regular assessment of pain for both inpatients and outpatients is suggested in order to evaluate the need for initiation
or continuation of multimodal therapy. Nursing staff should
conduct sedation assessment on all inpatients who are receiving
pain medication. Naloxone also should be prescribed when
factors that increase a risk of overdose are present.
A prescription drug monitoring program (PDMP)
should be regularly queried before opioids are prescribed.
Orthopaedic departments need to support opioid education
efforts for patients and clinicians. Clinical decision support
in the electronic medical record is beneﬁcial for prescribers
in order to minimize errors and provide information on multimodal medication and opioid dosing.
State Policy and the Opioid Epidemic
In the U.S., individual states have employed many ways to try to
ﬁght the opioid epidemic. These have included prescribing
limits and guidelines, mandatory patient and provider-level
prescription monitoring, standards of practice, prescriber education, expanded access to naloxone, and expanded access to
treatment. As described below, these initiatives have had mixed
results in ﬁghting the epidemic.
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Mandatory Prescription Monitoring
Every state except Missouri currently has a prescription monitoring program. In 32 states, the prescription monitoring program is mandatory. In 2012, Kentucky became the ﬁrst state to
establish such a program. In the ﬁrst year of the program,
Kentucky saw a 30% decrease in the concurrent prescribing
of opioids and sedatives, as well as a 25% decrease in deaths
from opioid abuse49. Most of these databases are updated daily,
although some are only updated weekly. Additionally, there is
inconsistent sharing of information among states. For example,
Tennessee has 8 border states, but it does not share data with 3
of the states that border it, resulting in incomplete information
for clinicians as they make decisions regarding prescribing. We
believe that a national prescription monitoring program would
be ideal.

risk for overdose do not have access to or contact with a
medical provider to receive a prescription. Increasing ease
of access to naloxone has been shown to be an effective way
to prevent opioid deaths. Forty-ﬁve states allow a third party
who is not at personal risk of an opioid overdose to be prescribed naloxone that can be administered to another person51. A ﬁnal manner in which to expand access to naloxone is
non-patient-speciﬁc prescriptions. This practice is allowed in
49 states. Non-patient-speciﬁc prescriptions authorize naloxone distribution to individuals and organizations that meet
speciﬁc criteria without needing to interact with a prescriber
beforehand. An example of this is allowing pharmacies to
dispense naloxone to individuals who request it without their
own prescription, a practice that is currently allowed in 41
states51.

Standards of Practice
Some states have passed legislation to create standards around
prescribing practices. One example is in the state of Rhode
Island. In 2017, Rhode Island passed legislation that created
the nation’s ﬁrst comprehensive statewide standards for treating overdose and opioid use in hospitals and emergency
departments50. A 3-level system of categorization that deﬁnes
each hospital and emergency department’s current capacity to
treat opioid-use disorder was established. The expectation was
that every hospital-based or freestanding emergency department will meet the requirements for a level-3 designation,
which represents a common foundation for all facilities that
demonstrate a solid commitment to this health-care problem
by creating the required infrastructure and subject-matter
expertise to appropriately treat these patients. Some of the
requirements for the level-3 designation include the
following:

Expanded Access to Addiction Treatment
Expanded access to treatment also has been shown to be
an important tool in the ﬁght against opioid addiction.
Unfortunately, universal access to addiction treatment has
been hampered because of the ﬁght regarding the expansion of Medicaid. Speciﬁcally, states that have expanded
access to Medicaid provide more of the lifesaving treatments, including medication-assisted therapy, which has
been shown to be effective in treating patients with opioid
addiction, compared with states that have not expanded
Medicaid 52 . Of the Medicaid-enrolled individuals in opioid
addiction treatment, those who use opioid antagonist therapy include 45% of individuals in states with coverage
for methadone maintenance and 30% of individuals in states
with block grant coverage only. In comparison, only 17% of
individuals in states with no coverage get medication-assisted
therapy52.
The United States is in the midst of an opioid crisis.
Clinicians have been part of the problem because of overprescribing of narcotics for perioperative pain management. Clinicians need to understand the pathophysiology
and science of addiction to improve perioperative management of pain for their patients. Multiple modalities for pain
management exist that decrease the use of narcotics. Physical strategies, cognitive strategies, and multimodal medication can all provide improved pain relief and decrease the
use of narcotics. National medical societies are developing
CPGs for pain management that incorporate multimodal
strategies and multimodal medication. Changes to policy
that improve provider education, access to naloxone, and
treatment for addiction can decrease narcotic misuse and
the risk of addiction. n

 Dispense the opioid antidote naloxone to all patients at
risk.
 Educate all patients who are prescribed opioids on safe
storage and disposal.
 Provide comprehensive discharge planning to people
who have overdosed.
 Screen all patients for substance use disorder.
 Report all overdoses to the state health department
within 48 hours.
 Offer patients peer recovery support services.
Prescriber Education
Twenty-three states and the District of Columbia have requirements for practitioners to obtain a certain number of continuing education hours in ‡1 of the following topics: prescribing
controlled substances, pain management, and identifying substance use disorders, among others50.
Expanded Access to Naloxone
Currently, all 50 states allow medical clinicians to prescribe
naloxone to patients who are at risk for opioid overdose51.
The concern, however, is that sometimes those at the highest
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